Field Trip Health Ltd.

Greetings and welcome to Field Trip First Quarter 2022 Earnings Results Call. At this time, all participants are in listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Elizabeth Barker, Senior Vice President of Investor Relations at KCSA. Elizabeth.

Thank you. Welcome, everyone, to Fieldtrip's first fiscal quarter of 2022 financial results conference call. Before I begin the call, I'm obligated to remind everyone that during the course of this conference call, management may be making some forward-looking statements that are based on current expectations and are subject to a number of risks and uncertainties that may cause actual results to differ materially from expectations. These results are outlined in the risk factors section of our filing and our disclosure materials. Any forward-looking statements should be considered in light of these factors. Please also note, as safe harbor, any outlook we present is as of today, and management does not undertake any obligations to revise any forward-looking statements in the future. On the phone with us today, we have Ronan Levy, co-founder and executive chairman, Joseph Del Moral, co-founder and CEO, and Donna Wong, CFO. I'll now turn the call over to Ronan to provide some insight into the company's strategic direction.

Thanks Elizabeth and good morning everyone. Welcome to our first quarter of fiscal 2022 earnings call. Well, it hasn't been long since our year end call. We have continued to make progress against our strategy, executing with speed and agility as we make the most of this huge opportunity that we have as trailblazers in the psychedelics market to help transform the current approach to mental health and build Fieldtrip into a revolutionary psychedelic therapy development company. I'm going to spend a few minutes now giving an overview of our strategy and explaining where we fit in the psychedelics market. As the psychedelics industry is still emerging, there are limited but growing number of players at this stage. We have implemented a differentiated strategy that we believe provides us with a de-risked path to drug development and commercialization, leveraging the synergies between our different businesses to collect data that can be used to ensure our approach is targeted, effective, and with an optimal go-to-market strategy. As many of you know, our main focus is on the development of a synthetic psychedelic drug FT-104 for use in mental health care with an initial focus on depressive disorders. Alongside this, we also offer psychedelic-assisted therapy that combines the science of psychedelic medicine with a personalized psychotherapy protocol to empower patients to enact lasting, meaningful change in their lives. At Fieldtrip Discovery, we are developing the next generation of psychedelic molecules. Our current candidate, FT-104, is designed to reduce the duration of psychedelic experience for patients and providers of psychedelic therapies. The combined efforts of Fieldtrip Discovery, our drug development arm, and our Fieldtrip Health network of sites for psychedelic medicine are operationally synergistic. The Fieldtrip Health Centers primarily exist to implement the research and commercialization goals of Fieldtrip Discovery. Through the psychedelic-assisted therapy offered at these sites, In addition to delivering unparalleled care to our patients, we can collect robust data that will allow us to identify areas of opportunity and unmet need. At our sites in North America, we use ketamine-assisted therapy, and in the Netherlands, we use natural psilocybin-assisted therapy. Both are proxies for future regulated and reimbursed psychedelics, in particular those developed at Field Trip Discovery. In addition, through our field trip health division, we are also building the physical infrastructure and technology platforms to deliver psychedelic therapy at scale, which also provides us an early opportunity to interface with providers, develop referral networks, interface with payers, all of which de-risk the path to drug approval and commercial success for this new therapy. While the psychedelics industry is in the early stages of its growth, psychedelic therapies are showing promise as highly effective and fast-acting treatment options. Our integrated business model is designed to optimize the path to regulatory and commercial success for our drug development candidates. We are proud of the rapid progress that we have made to date, establishing such a strong foundation from which to execute against this strategy. I'll now turn the call over to Joseph Belmoral, our CEO, to talk through our operational achievements in more detail and shed some more light on our plans for the remainder of the year.